True Health Technology Files for HKEX Listing, China’s No.1 in Percutaneous Surgical Robots

NewTimeSpace News: As disclosed by the Hong Kong Stock Exchange, Guangdong True Health Medical Technology Development Co., Ltd. filed for main board listing on May 31, 2026, with CICC and DBS Bank as joint sponsors. The application was confidentially submitted on December 8, 2025.
Founded in 2018, True Health is a pioneer and leader in the R&D and commercialization of percutaneous puncture and ablation surgical robots in China. Per CIC data, it has held the top market share in China’s percutaneous puncture and ablation surgical robot market for three consecutive years since 2022. Its core product, the TH-S percutaneous puncture surgical navigation and positioning system, is certified by the NMPA as a “domestic first-of-its-kind” independently developed system. The flagship TH-X MW is deemed an “international first-of-its-kind” image-guided navigation microwave ablation robot, and is also the first Class III innovative medical device approved by the NMPA in Hengqin.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.